TITLE

COMMENTARY: Combination disease-modifying antirheumatic drug therapy reduced work disability in early rheumatoid arthritis

AUTHOR(S)
Hunter, David
PUB. DATE
November 2004
SOURCE
ACP Journal Club;Nov/Dec2004, Vol. 141 Issue 3, p69
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a commentary on the study, which concluded that combination disease-modifying antirheumatic drug therapy reduced work disability in early rheumatoid arthritis (RA). The natural history of RA is characterized by poor outcome, with progressive joint damage and function loss in most patients. Therefore, the goal of treatment is not only to control pain, but also to reduce joint damage and disability. Work disability is a frequent and serious outcome of RA that can translate into less income for the patient and less productivity for society.
ACCESSION #
15303589

 

Related Articles

  • Combination disease-modifying antirheumatic drug therapy reduced work disability in early rheumatoid arthritis.  // ACP Journal Club;Nov/Dec2004, Vol. 141 Issue 3, p69 

    The article addresses the question how treatment with a combination of disease-modifying antirheumatic drugs (DMARDs) compares with a single DMARD for prevention of work disability in patients with early rheumatoid arthritis (RA). The article concludes that in patients with early rheumatoid...

  • The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study. Suda, Akiko; Nagaoka, Shouhei; Ohono, Shigeru; Ideguchi, Haruko; Soga, Takayoshi; Ishigatsubo, Yoshiaki // Modern Rheumatology (Springer Science & Business Media B.V.);Dec2008, Vol. 18 Issue 6, p609 

    We investigated the efficacy and safety of bucillamine administered as a second-line DMARD compared to administration as a first-line DMARD in the treatment of rheumatoid arthritis (RA). We conducted a retrospective cohort study and reviewed medical records of 86 patients with active RA who...

  • Abatacept In Focus. Cohen, Marc // Internet Journal of Rheumatology;2007, Vol. 3 Issue 1, p1 

    There have been considerable advances in the treatment of rheumatoid arthritis. However, many patients are found to be refractory to traditional disease-modifying antirheumatic drugs and the newer anti-cytokine therapies. Agents such as abatacept and rituximab now offer exciting new options for...

  • Romatoid Artrit ve Hastalığı Modifiye Edici Antiromatizmal Ä°laçlar. Güzel, Rengin // Turkish Journal of Physical Medicine & Rehabilitation / Turkiye ;abr2008, Vol. 54 Issue 2, p25 

    It has now been well established that in Rheumatoid Arthritis early treatment with disease modifying antirheumatic drugs (DMARDs) should be initiated to control the inflammatory activity, structural damage and function. Toxicity of the drugs should be monitored carefully. In cases with...

  • Romatoid Artrit ve HastaliÄŸi Modifiye Edici Antiromatizmal ilaçlar. Güzel, Rengin // Turkish Journal of Physical Medicine & Rehabilitation / Turkiye ;mai2008 Supplement, Vol. 54 Issue 1, p25 

    It has now been well established that in Rheumatoid Arthritis early treatment with disease modifying antirheumatic drugs (DMARDs) should be initiated to control the inflammatory activity, structural damage and function. Toxicity of the drugs should be monitored carefully. In cases with...

  • EFFECTIVENESS OF ADALIMUMAB FOR RHEUMATOID ARTHRITIS IN PATIENTS WITH A HISTORY OF ANTI-TNF ANTAGONIST THERAPY IN CLINICAL PRACTICE. Bomnardieri, S.; Ruiz, A. A.; Fardellone, P.; Geusens, P.; McKenna, F.; Unnebrink, K.; Oezer, U.; Kary, S.; Kupper, H.; Burmester, G. R. // Romanian Journal of Rheumatology;2008, Vol. 17 Issue 1, p34 

    Objective. To evaluate the effectiveness and safety of adalimumab in patients with rheumatoid arthritis (RA) who previously discontinued tumour necrosis factor (TNF) antagonists for any reason in clinical practice. Methods. ReAct (Research in Active Rheumatoid Arthritis) was a large, open-label...

  • Rheumatoid Arthritis: Early Treatment With Corticosteroids and Nonsteroidal Anti-inflammatory Drugs. Ruoff, Gary // Journal of Family Practice;Feb2014 Supplement, Vol. 63, pS27 

    The article offers information on the early treatment of rheumatoid arthritis (RA) with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Topics discussed include the disease-modifying antirheumatic drug (DMARD) therapy, criteria for diagnosis, and the three U.S. Food and Drug...

  • Prevalence of and predictive factors for sustained diseasemodifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.  // International Journal of Advances in Rheumatology;2009, Vol. 7 Issue 4, p126 

    This study of two cohorts of rheumatoid arthritis (RA) patients revealed that up to 15% of those who were treated with conventional therapy (disease-modifying anti-rheumatic drugs [DMARDs] or nonsteroidal antiinflammatory drugs) had sustained DMARD-free remission. Furthermore, this remission...

  • Sulfasalazine: A Review of its Use in the Management of Rheumatoid Arthritis. Plosker, Greg L.; Croom, Katherine F. // Drugs;2005, Vol. 65 Issue 13, p1825 

    Sulfasalazine (salazosulfapyridine) [Azulfidine®, Salazopyrin®] is a well established disease-modifying antirheumatic drug (DMARD) used in the treatment of patients with rheumatoid arthritis. Clinical trials with sulfasalazine have used an array of measures of disease activity, such as the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics